I 
110TH CONGRESS 
1ST SESSION H. R. 2184 
To amend the Medicare Prescription Drug, Improvement, and Modernization 
Act of 2003 to expand comparative effectiveness research and to increase 
funding for such research to improve the value of health care. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 7, 2007 
Mr. ALLEN (for himself and Mrs. EMERSON) introduced the following bill; 
which was referred to the Committee on Ways and Means, and in addi-
tion to the Committee on Energy and Commerce, for a period to be sub-
sequently determined by the Speaker, in each case for consideration of 
such provisions as fall within the jurisdiction of the committee concerned 
A BILL 
To amend the Medicare Prescription Drug, Improvement, 
and Modernization Act of 2003 to expand comparative 
effectiveness research and to increase funding for such 
research to improve the value of health care. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Enhanced Health Care 
Value for All Act of 2007’’. 
VerDate Aug 31 2005 
22:37 May 08, 2007
Jkt 049200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H2184.IH
H2184
pwalker on PROD1PC71 with BILLS
SEC. 2. RESEARCH ON COMPARATIVE EFFECTIVENESS OF 
HEALTH CARE ITEMS AND SERVICES. 
(a) EXPANSION
OF SCOPE
OF RESEARCH.—Sub-
section (a) of section 1013 of the Medicare Prescription 
Drug, Improvement, and Modernization Act of 2003 (Pub-
lic Law 108–173) is amended— 
(1) in paragraph (1)— 
(A) in subparagraph (A)— 
(i) by striking ‘‘programs established 
under titles XVIII, XIX, and XXI of the 
Social Security Act’’ and inserting ‘‘Fed-
eral health care programs (as defined in 
subparagraph (C))’’; 
(ii) by striking ‘‘shall conduct and 
support research’’ and inserting ‘‘shall con-
duct and support research, which may in-
clude clinical research,’’; 
(iii) in clause (i), by striking ‘‘and’’ at 
the end; 
(iv) in clause (ii), by striking the pe-
riod at the end and inserting ‘‘; and’’; and 
(v) by adding at the end the following: 
‘‘(iii) gaps in current research which 
may necessitate research beyond system-
atic reviews of existing evidence.’’; 
VerDate Aug 31 2005 
22:37 May 08, 2007
Jkt 049200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H2184.IH
H2184
pwalker on PROD1PC71 with BILLS
(B) by adding at the end the following new 
subparagraph: 
‘‘(C) FEDERAL HEALTH CARE PROGRAMS 
DEFINED.—For purposes of this section, the 
term ‘Federal health care program’ means each 
of the following: 
‘‘(i) Any program established under 
title XVIII, XIX, or XXI of the Social Se-
curity Act. 
‘‘(ii) The Federal employees health 
benefits program under chapter 89 of title 
5, United States Code. 
‘‘(iii) A health program operated 
under title 38, United States Code, by the 
Department of Veterans Affairs. 
‘‘(iv) The TRICARE program under 
chapter 55 of title 10, United States Code. 
‘‘(v) A medical care program of the 
Indian Health Service or of a tribal organi-
zation.’’; 
(2) in paragraph (2)— 
(A) in subparagraph (C)(i), by striking 
‘‘the programs established’’ and inserting ‘‘Fed-
eral health care programs, including the pro-
grams established’’; 
VerDate Aug 31 2005 
22:37 May 08, 2007
Jkt 049200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H2184.IH
H2184
pwalker on PROD1PC71 with BILLS
(B) in subparagraph (C)(ii), by striking 
‘‘and’’ at the end; 
(C) in subparagraph (C)(iii), by striking 
the period at the end and inserting ‘‘; and’’; 
(D) by inserting after subparagraph (C) 
the following: 
‘‘(iv) shall provide for edu-
cation to physicians, other health 
care providers, and the public 
(including 
patients 
and 
con-
sumers) about the information on 
comparative effectiveness that is 
available as a result of research 
funded under this section.’’; and 
(E) by adding at the end the following: 
‘‘(D) COMPARATIVE EFFECTIVENESS ADVI-
SORY BOARD.— 
‘‘(i) IN GENERAL.—Effective as of the 
date of the enactment of the Enhanced 
Health Care Value for All Act of 2007, the 
stakeholder group consulted for purposes 
of subparagraph (C)(1) shall be known as 
the Comparative Effectiveness Advisory 
Board. Any reference in a law, map, regu-
lation, document, paper, or other record of 
VerDate Aug 31 2005 
22:37 May 08, 2007
Jkt 049200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H2184.IH
H2184
pwalker on PROD1PC71 with BILLS
the United States to such stakeholder 
group shall be deemed to be a reference to 
the Comparative Effectiveness Advisory 
Board. 
‘‘(ii) COMPOSITION OF BOARD.—The 
members of the Comparative Effectiveness 
Advisory Board shall consist of— 
‘‘(I) the Director of the Agency 
for Healthcare Research and Quality; 
and 
‘‘(II) up to 14 additional mem-
bers who shall represent broad con-
stituencies of stakeholders including 
clinicians, patients, researchers, third- 
party payers, consumers of Federal 
and State beneficiary programs, and 
health care industry professionals. 
‘‘(iii) APPOINTMENT; 
TERMS.—The 
Comptroller General of the United States 
shall appoint the members of the Compara-
tive Effectiveness Advisory Board. Each 
member shall be appointed for a term of 2 
years. The members appointed for the first 
term following the date of the enactment 
of the Enhanced Health Care Value for All 
VerDate Aug 31 2005 
22:37 May 08, 2007
Jkt 049200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H2184.IH
H2184
pwalker on PROD1PC71 with BILLS
Act of 2007 shall be appointed not later 
than 90 days after such date of enactment. 
Any member serving on the Advisory 
Board as of the date of the enactment of 
the Enhanced Health Care Value for All 
Act of 2007 may continuing serving 
through the end of the member’s term. 
‘‘(iv) CONFLICTS
OF
INTEREST.—In 
appointing the members of the Compara-
tive Effectiveness Advisory Board (and the 
members of any panel that reports to the 
Board), the Comptroller General of the 
United States shall take into consideration 
any financial conflicts of interest. 
‘‘(E) ADDITIONAL AUTHORITIES.—In addi-
tion to any authorities vested in the Compara-
tive Effectiveness Advisory Board as of the day 
before the date of the enactment of the En-
hanced Health Care Value for All Act of 2007, 
the Comparative Effectiveness Advisory Board 
shall have the following authorities: 
‘‘(i) To provide input on research pri-
orities. 
‘‘(ii) To recommend how to organize 
research funded under this section taking 
VerDate Aug 31 2005 
22:37 May 08, 2007
Jkt 049200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H2184.IH
H2184
pwalker on PROD1PC71 with BILLS